Tag: MOSY

Blue Horseshoe Stocks: PIRS Review & More

Pieris Pharmaceuticals Inc. PIRS – Review

Of all the types of plays we search for, bottom watch plays can require the most amount of patience as compared to other quick-strike ideas that we formulate. We highlighted PIRS as such back in mid-February, and over the past quarter, the stock has produced some very favorable results in two distinct runs.

When we initially signaled our interest in this stock, or shortly thereafter, it was trading for as little as 2.83 and over the course of the next two months, it gradually made its way to 4.00 (+41%). After a pullback down near its original level at 2.81 halfway through last month, the stock has begun to run once again. This time it has reached all new highs, with the stock changing hands for as much as 4.68/share on Friday. That second push allowed us to see an overall increase of 67%

We wouldn’t be at all surprised to have to come back to PIRS once again in the near future. In addition to the company’s joint clinical venture with pharma super giant AstraZeneca, the stock itself has recently received analyst upgrades that could just be the beginning of PIRS’s next leg-up.

Xalles Holdings, Inc. XALL

We are also looking at the incredible momentum recently built up by XALL, which has been assisted by the resurgence of Bitcoin here in 2019, which began in January in the mid-$3000 range, and has persisted to the present time to the current highs near $8700.

The company also recently decreased its public float by around 50%, making it that much easier for the stock to move. We’ll be interested to continue to monitor its progress, especially if the latest Bitcoin boom continues to persist as it has in recent months.

Extended Watchlist:
DRRX, CBLK, BLNK, CTRV, MOSY, SNSS, NVCN, ATVI, LAHO(>>News Alert)

Blue Horseshoe Stocks: Huge SPY Gains, AMPG New Highs

Amplitech Group, Inc. AMPG – Update

We were all over AMPG once again last week, as we have been since the beginning of April when we initiated coverage on the stock. The move on Friday followed the news that the company virtually doubled their yearly expected sales via acquisition of a long-established, privately-held company.

AMPG made a 15% intraday push to a new high of .063 which works out to an overall increase of 47% over the .043 low we observed on the day of our initial report on the company (04/01/19). It also came with the biggest single-session volume recorded over these past six weeks.

Friday’s gains pushed AMPG‘s market cap above the $3M mark, although we would argue that even at that price, the stock is still grossly undervalued at present. Especially when one considers that it’s notably less than the combined expected annual sales of AMPG and the pending acquisition target, which you can read about in the link to the news above, or in the 8-K filed this morning.

We remain excited for the future potential of this company, and its stock. Stay tuned for future updates and be sure to commence your own due diligence, starting at AmpliTechInc.com.

SPDR S&P500 ETF (SPY) – Recap

Along with our coverage of AMPG on Friday morning, we also included a fresh options idea for the SPY that was incredibly successful, and reinforcing the strength of our commitment to producing the very best ideas that we can.

We cited the SPY Weekly $284-285.50 Calls, and with the help of a strong second half of the day for the markets as a whole, yielded the following enormous gain opportunities:

$284 Calls – Range: .59-4.82 – Max Gain: 717%
$284.50 Calls – Range: .43-4.20  – Max Gain: 877%
$285 Calls – Range: .30-3.84 – Max Gain: 1180%
$285.50 Calls – Range: .21-3.29  – Max Gain: 1467%

Extended Watchlist:
TVIX, AXNX, IZEA, MOSY, SQQQ, CPRX

Blue Horseshoe Stocks: SPY Puts Recap & More

SPDR S&P 500 ETF (SPY) – Review

We went bearish on the SPY yesterday morning, and offered up a set of corresponding ideas in the options chain. We signaled our interest in the SPY 10/08 $288.50-$287.50 Puts which just had the one session before expiration.

It turned out to be a great rapid-strike play for anyone who cared to take advantage. Every single contract in our designated group produced legitimately impressive multi-bag intraday gain opportunities.

$288.50 Puts – Range: .71-2.90 – Max Gain: 308%
$288 Puts – Range: .47-2.50 – Max Gain: 432%
$287.50 Puts – Range: .31-2.00 – Max Gain: 545%

Kala Pharmaceuticals, Inc. KALA

Catching our eye as a potential bottom bounce play this morning is KALA, which is presently exhibiting all of the bottom play indicators we typically look for. The RSI is in indicating that the stock is oversold, but with strength rising, and the MACD is sharply converging toward an impending cross.

Meanwhile the PPS showed its first inclination yesterday of attempting to fill in the topside gap we can also plainly see on the snapshot below. We’re going yto place the stock on watch for a continued rebound, and also tag the KALA 01/18 $10 & 12.50 Calls for observation in the days and weeks ahead.




CorMedix, Inc. CRMD

We placed CRMD on watch beginning on last Monday, October 1st, and subsequent to that report, would observe a low of 1.06 in the stock. Yesterday, CRMD attained a new high of 1.65, marking a notable 56% upswing in just a weeks time.

Extended Watchlist: 
CZNI, AGRX, OGEN, MOSY, HELE, PYX, DGLY